CLINICAL STUDY

Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients

Fernando Cordido1,2, Paula Alvarez-Castro1, Maria Luisa Isidro1, Felipe F Casanueva4 and Carlos Dieguez3

1 Department of Endocrinology, Hospital Juan Canalejo, 2 Department of Medicine University of La Coruña and 3 Departments of Physiology and Medicine, University of Santiago, La Coruña and Santiago, Spain

(Received should be addressed to F Cordido, Servicio de Endocrinología, Hospital Juan Canalejo, Xubias de Arriba 84, 15006 La Coruña, Spain; Email: fernando_cordido@canalejo.org)

Abstract

Objective: It has been gradually realized that GH may have important physiological functions in adult humans. The biochemical diagnosis of adult GHD is established by provocative testing of GH secretion. The insulin-tolerance test (ITT) is the best validated. The ITT has been challenged because of its low degree of reproducibility and lack of normal range, and is contra-indicated in common clinical situations. Furthermore, in severely obese subjects the response to the ITT frequently overlaps with those found in non-obese adult patients with GHD.

Design: The aim of the present study was to evaluate the diagnostic capability of four different stimuli of GH secretion: ITT, GHRH, GHRH plus acipimox (GHRH+Ac), and GHRH plus GHRP-6 (GHRH+GHRP-6), in two pathophysiological situations: hypopituitarism and obesity, and normal subjects.

Methods: Eight adults with hypopituitarism (four female, four male) aged 41–62 years (48.8±1.4 years), ten obese normal patients (five female, five male) aged 38–62 years (48.1±2.5 years), with a body mass index of 34.2±1.2 kg/m², and ten normal subjects (five female, five male) aged 33–62 years (48.1±2.8 years) were studied. Four tests were performed on each patient or normal subject: An ITT (0.1 U/kg, 0.15 U/kg for obese, i.v., 0 min), GHRH (100 μg, i.v., 0 min), GHRH (100 μg, i.v., 0 min) preceded by acipimox (250 mg, orally, at −270 min and −60 min) (GHRH+Ac); and GHRH (100 μg, i.v., 0 min) plus GHRP-6 (100 μg, i.v., 0 min) (GHRH + GHRP-6). Serum GH was measured by radioimmunoassay. Statistical analyses were performed by Wilcoxon rank sum and by Mann–Whitney tests.

Results: After the ITT the mean peak GH secretion was 1.5±0.3 μg/l for hypopituitary, 10.1±1.7 μg/l (P < 0.05 vs hypopituitary) for obese and 17.8±2.0 μg/l (P < 0.05 vs hypopituitary) for normal. GHRH-induced GH secretion was 2±0.7 μg/l for hypopituitary, 3.9±1.2 μg/l (P = NS vs hypopituitary) for obese and 22.2±3.8 μg/l (P < 0.05 vs hypopituitary) for normal. After GHRH+Ac, mean peak GH secretion was 3.2±1.4 μg/l for hypopituitary, 14.2±2.7 μg/l (P < 0.05 vs hypopituitary) for obese and 35.1±5.2 μg/l (P < 0.05 vs hypopituitary) for normal. GHRH+GHRP-6 induced mean peak GH secretion of 4.1±0.9 μg/l for hypopituitary, 38.5±6.5 μg/l (P < 0.05 vs hypopituitary) for obese and 68.1±5.5 μg/l (P < 0.05 vs hypopituitary) for normal subjects. Individually considered, after ITT, GHRH or GHRH+Ac, the maximal response in hypopituitary patients was lower than the minimal response in normal but higher than the minimal response in obese subjects. In contrast, after GHRH+GHRP-6 the maximal response in hypopituitary patients was lower than the minimal response in normal and obese subjects.

Conclusions: This study suggests that, in this group of patients, although both acipimox and GHRP-6 partially reverse the functional hyposomatotropism of obesity after GHRH, but are unable to reverse the organic hyposomatotropism of hypopituitarism, the combined test GHRH+GHRP-6 most accurately distinguishes both situations, without the side effects of ITT.

European Journal of Endocrinology 149 117–122

Introduction

It has been gradually realized that GH may have important physiological functions in adult humans. Several studies have shown that GH deficiency (GHD) in adults (GHDAd) is associated with abnormalities in body composition, metabolic derangements and sub-optimal physical performances, and that these impairments improve with GH replacement therapy (1–3).
Subjects and methods

Eight adults with hypopituitarism and adult onset GHD (four female, four male) aged 41–62 years (48.8 ± 1.4 years), ten obese normal patients (five female, five male) aged 38–62 years (48.1 ± 2.5 years), with a body mass index (BMI) of 34.2 ± 2.8 kg/m², and ten normal subjects (five female, five male) aged 33–62 years (48.1 ± 2.8 years) were studied.

The diagnosis of hypopituitarism was established by a history of structural pituitary or hypothalamic lesion treated with surgery and/or radiotherapy necessitating end-organ hormonal substitution for any combination of a thyroid, adrenal or gonadal failure. All hypopituitary patients showed an impaired response to an ITT (0.1 U/kg, i.v.), with a peak GH secretion of less than 3 μg/l. Where indicated, patients were receiving physiologic replacement doses of l-thyroxin and/or glucocorticoids and/or gonadal steroids. The etiologic diagnosis in the hypopituitary patients was: four non-functioning pituitary adenomas, one surgery-treated pituitary macroadenoma, one Sheehans’ syndrome, one empty sella turcica, and one idiopathic hypopituitarism.

Obese patients had a BMI greater than 30 kg/m² (normal range 20–25 kg/m²). Normal subjects had a BMI between 20–25 kg/m². None of the obese or normal subjects had diabetes mellitus or other medical problems, nor were they taking any drugs. All subjects gave informed consent and approval for this study was obtained from the hospital committee. The subjects had been eating a weight-maintaining diet for several weeks prior to the study.

Four tests were carried out for each patient or normal subject, each one separated by at least 1 week. The tests were started at 0900 h after an overnight fast, with the subjects recumbent. The tests carried out were: ITT (0.1 U/kg, 0.15 U/kg for obese patients, i.v., 0 min); GHRH (100 μg, i.v., 0 min); GHRH (100 μg, i.v., 0 min) preceded by acipimox (250 mg, orally, at −270 min and −60 min) (GHRH + Ac); and GHRH (100 μg, i.v., 0 min) plus GHRP-6 (100 μg, i.v., 0 min) (GHRH + GHRP-6). Blood samples were obtained every 15 min over the following 90 min of testing through an indwelling catheter placed in a forearm vein and kept patent by a slow infusion of saline.

Serum GH was measured by radioimmunoassay (Nichols Institute, San Juan Capistrano, CA, USA) with a sensitivity of 0.04 μg/l and with intra-assay coefficients of variation of 4.2, 2.9 and 2.8% for low, medium and high plasma GH levels, respectively. Free fatty acid (FFA) levels were determined by an enzymatic colorimetric method (NEFA-HA, Wako, Zaragoza, Spain). All samples from a given subject were analyzed in the same assay run. Hormone levels are presented as absolute values or as the mean GH peak.

Statistical analyses were performed by Wilcoxon rank sum between related groups and by Mann–Whitney tests between different groups. Results are expressed as mean ± S.E.M. and P < 0.05 was considered significant.

Results

The response of the groups of patients and normal subjects are presented in Tables 1–3.

After the ITT the mean peak GH secretion was 1.5 ± 0.3 μg/l for hypopituitary patients, 10.1 ± 1.7 μg/l (P < 0.05 vs hypopituitary) for obese patients, and 17.8 ± 2.0 μg/l (P < 0.05 vs hypopituitary) for normal subjects. Mean peak GHRH-induced GH secretion was 2 ± 0.7 μg/l for hypopituitary patients, 3.9 ± 1.2 μg/l (P = NS vs hypopituitary) for obese patients, and 22.2 ± 3.8 μg/l (P < 0.05 vs hypopituitary) for normal subjects. After GHRH + Ac the mean peak GH secretion was 3.3 ± 1.4 μg/l for hypopituitary patients, 14.2 ± 2.7 μg/l (P < 0.05 vs hypopituitary) for obese patients, and 35.1 ± 5.2 μg/l (P < 0.05 vs hypopituitary) for normal subjects. Mean peak GHRH
Table 1 Peak GH (µg/l) secretion in hypopituitary patients after different stimuli of GH secretion. Patients’ ages (in years) and gender are given in brackets.

<table>
<thead>
<tr>
<th>Patient</th>
<th>ITT</th>
<th>GHRH</th>
<th>GHRH + Ac</th>
<th>GHRH + GHRP-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (53, w)</td>
<td>3.8</td>
<td>5.8</td>
<td>5.6</td>
<td></td>
</tr>
<tr>
<td>2 (54, w)</td>
<td>4.0</td>
<td>4.1</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>3 (62, m)</td>
<td>2.9</td>
<td>7.1</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>4 (47, w)</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>5 (29, m)</td>
<td>1</td>
<td>2.7</td>
<td>7.5</td>
<td></td>
</tr>
<tr>
<td>6 (61, m)</td>
<td>0.2</td>
<td>0.3</td>
<td>5.2</td>
<td></td>
</tr>
<tr>
<td>7 (43, w)</td>
<td>1.9</td>
<td>2.3</td>
<td>6.7</td>
<td></td>
</tr>
<tr>
<td>8 (41, m)</td>
<td>1.8</td>
<td>2.7</td>
<td>1.9</td>
<td></td>
</tr>
</tbody>
</table>

X±SEM: 1.5±0.3 2.0±0.7 3.3±1.4 4.1±0.9

w, female; m, male.

Table 2 Peak GH (µg/l) secretion in obese subjects after different stimuli of GH secretion. Subjects’ ages (in years) and gender are given in brackets.

<table>
<thead>
<tr>
<th>Subject</th>
<th>ITT</th>
<th>GHRH</th>
<th>GHRH + Ac</th>
<th>GHRH + GHRP-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (53, w)</td>
<td>10.6</td>
<td>0.7</td>
<td>7.4</td>
<td>15.3</td>
</tr>
<tr>
<td>2 (42, w)</td>
<td>14.3</td>
<td>2.4</td>
<td>15.8</td>
<td>14.7</td>
</tr>
<tr>
<td>3 (49, w)</td>
<td>16.6</td>
<td>1.5</td>
<td>6.2</td>
<td>55.2</td>
</tr>
<tr>
<td>4 (41, m)</td>
<td>11.1</td>
<td>11.5</td>
<td>36</td>
<td>41</td>
</tr>
<tr>
<td>5 (43, w)</td>
<td>16.6</td>
<td>2.3</td>
<td>17</td>
<td>86</td>
</tr>
<tr>
<td>6 (38, m)</td>
<td>12.4</td>
<td>9.9</td>
<td>14.9</td>
<td>41</td>
</tr>
<tr>
<td>7 (62, m)</td>
<td>3.8</td>
<td>2.9</td>
<td>13.3</td>
<td>35.3</td>
</tr>
<tr>
<td>8 (54, w)</td>
<td>10.4</td>
<td>3.3</td>
<td>11.5</td>
<td>33.4</td>
</tr>
<tr>
<td>9 (44, m)</td>
<td>3.1</td>
<td>2.8</td>
<td>8.2</td>
<td>39.2</td>
</tr>
<tr>
<td>10 (55, m)</td>
<td>2.3</td>
<td>1.9</td>
<td>11.6</td>
<td>23.5</td>
</tr>
</tbody>
</table>

X±SEM: 10.1±1.7 3.9±1.2 14.2±2.7 38.5±6.5

Table 3 Peak GH (µg/l) secretion in normal subjects after different stimuli of GH secretion. Subjects’ ages (in years) and gender are given in brackets.

<table>
<thead>
<tr>
<th>Subject</th>
<th>ITT</th>
<th>GHRH</th>
<th>GHRH + Ac</th>
<th>GHRH + GHRP-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (33, m)</td>
<td>18.7</td>
<td>41.8</td>
<td>23</td>
<td>53.3</td>
</tr>
<tr>
<td>2 (47, m)</td>
<td>15.0</td>
<td>19.6</td>
<td>35.8</td>
<td>86.1</td>
</tr>
<tr>
<td>3 (41, m)</td>
<td>25.3</td>
<td>19.6</td>
<td>48.8</td>
<td>76.7</td>
</tr>
<tr>
<td>4 (43, m)</td>
<td>26</td>
<td>25.5</td>
<td>38.7</td>
<td>63.2</td>
</tr>
<tr>
<td>5 (52, w)</td>
<td>28.5</td>
<td>45.1</td>
<td>13.7</td>
<td>52.7</td>
</tr>
<tr>
<td>6 (44, w)</td>
<td>15.5</td>
<td>10.8</td>
<td>68.4</td>
<td>73.4</td>
</tr>
<tr>
<td>7 (62, m)</td>
<td>11.2</td>
<td>19.7</td>
<td>44.2</td>
<td>31.9</td>
</tr>
<tr>
<td>8 (51, m)</td>
<td>10.3</td>
<td>18.5</td>
<td>35.3</td>
<td>78.8</td>
</tr>
<tr>
<td>9 (49, w)</td>
<td>14.1</td>
<td>11.5</td>
<td>30.7</td>
<td>80.7</td>
</tr>
<tr>
<td>10 (59, m)</td>
<td>13.3</td>
<td>9.9</td>
<td>12.8</td>
<td>84.3</td>
</tr>
</tbody>
</table>

X±SEM: 17.8±2.0 22.2±3.8 35.1±5.2 68.1±5.5

plus GHRP-6 induced GH secretion was 4.1±0.9 µg/l for hypopituitary patients, 38.5±6.5 µg/l (P < 0.05 vs hypopituitary) for obese patients, and 68.1±5.5 µg/l (P < 0.05 vs hypopituitary) for normal subjects.

The administration of acipimox induced a FFA reduction during the entire test that was similar for hypopituitary patients, obese patients and normal subjects.

The differential between normal subjects and hypopituitary patients for GHRH + GHRP-6 (64 µg/l) was higher (P < 0.05) than for the ITT (16.3 µg/l), GHRH (20.2 µg/l), and GHRH + Ac (31.8 µg/l). The differential between obese and hypopituitary patients for GHRH + GHRP-6 was (34.4 µg/l) higher (P < 0.05) than for the ITT (8.6 µg/l), GHRH (1.9 µg/l) and GHRH + Ac (10.9 µg/l).

Individually considered, after ITT the maximal response in hypopituitary subjects was 2.5 µg/l. This response was lower than the minimal response in normal subjects of 10.3 µg/l but higher than the minimal response in obese subjects of 2.3 µg/l. After GHRH stimuli the maximal response in hypopituitary subjects was 4 µg/l. This response was lower than the minimal response in normal subjects of 9.9 µg/l but higher than the minimal response in obese subjects of 0.7 µg/l. After GHRH + Ac stimuli the maximal response in hypopituitary subjects was 7.1 µg/l. This response was lower than the minimal response in normal subjects of 12.8 µg/l but higher than the minimal response in obese subjects of 6.2 µg/l. In contrast, after GHRH + GHRP-6 stimuli the maximal response in hypopituitary subjects was 7.5 µg/l. This response was lower than the minimal response in normal subjects of 31.9 µg/l and also lower than the minimal response in obese subjects of 14.7 µg/l.

No significant side effects were observed with the different tests. After ITT clinical symptoms of hypoglycemia were present in all patients. One hypopituitary patient, one obese patient and one normal subject experienced a mild transient facial flushing after the first dose of acipimox. No side effects were reported in the other tests and no test had to be stopped.
Discussion

This study demonstrates that when studied in a small group of hypopituitary patients with adult onset GHD, obese patients and normal subjects, GHRH+GHRP-6 is the most reliable test for the diagnosis of GHD compared with ITT, GHRH and GHRH+Ac.

The approach to the diagnosis of GHD requires a high index of suspicion. It should include adults who in childhood received GH for pituitary dwarfism and adults with known or suspected pituitary disease (8, 17). Some recent studies have suggested that the presence of three or more pituitary hormone deficiencies or serum IGF-I concentrations with a certain specific assay could be used for the diagnosis of GHD (18). Due to its pronounced intra-individual fluctuations, determination of basal plasma concentrations of GH is of no value for the diagnosis of GHD, and considerable overlap with healthy control groups precludes determination of IGF-I and IGFBP-3 (19, 20), analysis of GH pulses (21), and/or GH determination in pooled serum samples or in urine (22). Therefore, most investigators agree that stimulation tests are indispensable to define GHD (19–21, 23). The insulin hypoglycemia test is the diagnostic test of choice for GHD (5). The criteria for profound GHD is met if the patient is symptomatic of hypoglycemia, the blood glucose is below 2.2 mmol/l, and the peak GH response is less than 3 μg/l (8). It is in these patients, who for the most part had a peak GH response to ITT of less than 3 μg/l, that beneficial responses with GH treatment have been observed (2, 3, 24). The ITT may not be the best tool for the diagnosis of GHD. The reproducibility of the ITT has been questioned in normal adults (7). A reference for the ITT will be difficult to establish, and it may be impossible to evaluate the possible influences of sex, age, body composition, and cortisol levels in ITT-stimulated GH levels, as patients find the ITT unpleasant. Furthermore the ITT is potentially hazardous (25).

Some recent studies have evaluated alternative tests for the diagnosis of GHD (9–16, 26) and have found that those tests could be used for the diagnosis of that situation. The GHRH+GHRP-6 test has been considered a convenient, safe and reliable test for GHD and is not confounded by clinical factors, which are known to alter GH secretory patterns. In the study by Popovic et al. (9) an evoked GH concentration of >15 μg/l accurately distinguished between healthy and GH-deficient adults. But there have not been studies comparing different alternative tests for the diagnosis of GHD. As suggested by Ho (27), the problem of false-negative results is probably not completely solved. Since GHRH and GHRP-6 act directly on the pituitary, it is possible that their administration restored GH secretion in patients who had a deficiency of these secretagog because of hypothalamic disease. This possibility is supported by the finding that some patients with idiopathic GHD, identified by a poor response to ITT, show an exuberant response to combined administration of GHRH and a GHRP analog (28, 29). Thus the combined test may best be used to assess patients with pituitary disease. Among GH-deficient patients who may have substantial hypothalamic dysfunction, the ITT remains the preferred test since it stimulates GH secretion indirectly through the hypothalamus (27). In contrast, it has been suggested that GH secretagogues may have a role in the diagnosis of GHD even in treated acromegaly (12).

Obesity-related limitation of GH secretion in response to all stimuli has attracted considerable study. Although enhancement of GH clearance is a contributing factor (30), the main altered mechanism in obesity is the impaired GH secretion, either stimulated or spontaneous (31, 32). We and others (31) have found that in obese subjects GH secretion is greatly impaired, and could be confused with the syndrome of GHD. Obesity is probably the most important confounding factor for the diagnosis of GHD. We have previously studied the response of obese normal subjects and compared that with the response of hypopituitary patients. The GH response of obese normal patients and obese adults with hypopituitarism was similar after GHRH alone. In contrast, the GH response after GHRH+Ac was markedly decreased in obese adult patients with hypopituitarism compared with obese normal patients. We conclude that GH secretion after GHRH+Ac administration is reduced in obese adult patients with hypopituitarism when compared with obese normal patients, and that testing with GHRH+Ac is safe and free from side effects and could be used for the diagnosis of GHD (33, 34). Recent studies have confirmed this data in patients that have undergone pituitary surgery (26).

After GHRH+GHRP-6 the maximal response in hypopituitary subjects was lower than the minimal response in normal subjects and lower than the minimal response in obese subjects. In contrast, after ITT, GHRH or GHRH+Ac, the maximal response in hypopituitarism was lower than the minimal response in normal subjects, but higher than the minimal response in obese subjects. The GHRH+GHRP-6 test best distinguishes the decreased GH secretion of obesity from GHD. In agreement with these data we have also found that the differential between normal subjects or obese patients and hypopituitary patients for GHRH+GHRP-6 was higher than for ITT, GHRH or GHRH+Ac. The main limitation of our study is the small number of patients studied and we think that further studies are still needed, including younger subjects with GHD, to confirm our data. If we want better criteria for GHD in the near future it would probably need to be based on outcomes after GH therapy (23).

In conclusion, this study suggests that in this group of patients, although both acipimox and GHRP-6 partially reverse the functional hyposomamotropism
of obesity after GHRH, but are unable to reverse the organic hyposomatotropism of hypopituitarism, the combined GHRH+GHRP-6 test most accurately distinguishes both situations, without the side effects of ITT.

Acknowledgements

This work was supported by a grant from Xunta de Galicia (PGIDT00PX1000PR) and FIS of the Instituto de Salud Carlos III (PI021479 and G03/028).

References


16 Petersenn S, Jung R & Bed FU. Diagnosis of GH deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test. European Journal of Endocrinology 2002 146 667–672.

www.eje.org
32 Cordido F, Dieguez C & Casanueva FF. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine or hypoglycemia in normal and obese subjects. *Journal of Clinical Endocrinology and Metabolism* 1990 **70** 1361–1370.


Received 3 April 2003
Accepted 21 May 2003